Nisa Investment Advisors LLC Buys 377 Shares of Repligen Co. (NASDAQ:RGEN)

Nisa Investment Advisors LLC raised its stake in shares of Repligen Co. (NASDAQ:RGEN) by 70.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 910 shares of the biotechnology company’s stock after acquiring an additional 377 shares during the period. Nisa Investment Advisors LLC’s holdings in Repligen were worth $164,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fortis Capital Advisors LLC bought a new position in shares of Repligen in the 4th quarter worth approximately $35,000. Park Place Capital Corp lifted its stake in shares of Repligen by 90.2% in the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 120 shares during the period. Signaturefd LLC lifted its stake in shares of Repligen by 44.1% in the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 86 shares during the period. UniSuper Management Pty Ltd bought a new position in shares of Repligen in the 2nd quarter worth approximately $57,000. Finally, Milestone Investment Advisors LLC bought a new position in shares of Repligen in the 3rd quarter worth approximately $61,000. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock valued at $5,039,532 in the last three months. 1.20% of the stock is currently owned by corporate insiders.

Repligen Price Performance

NASDAQ RGEN opened at $157.14 on Friday. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The stock has a market cap of $8.77 billion, a price-to-earnings ratio of 218.25, a PEG ratio of 5.27 and a beta of 1.02. The company’s 50 day moving average is $189.09 and its two-hundred day moving average is $173.09. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The company had revenue of $155.74 million for the quarter, compared to analysts’ expectations of $155.38 million. During the same quarter last year, the business earned $0.68 EPS. The firm’s revenue was down 16.6% compared to the same quarter last year. As a group, research analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. KeyCorp increased their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus increased their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.